|
Daniel Levitt joined Cerimon as its Executive Vice President, Research and Development in January 2007. Dr. Levitt has over 20 years of experience leading research and development programs at both biotechnology and pharmaceutical companies. Before joining Cerimon, Dr. Levitt served as Dynavax Technologies’ Chief Medical Officer and Head of Clinical and Regulatory Affairs. Prior, Dr. Levitt was Chief Operating Officer and Head of Research and Development at Affymax, Inc., where he oversaw all research, development, and commercialization operations. Dr. Levitt also spent six years at Protein Design Labs, Inc. (PDL), completing his tenure as President of R&D from 2000 to 2002. Prior to PDL, Dr. Levitt held senior management positions at Geron Corporation, where he served as Vice President, Drug Discovery and Development, and Chief Medical Officer at Sandoz Pharma Ltd., where he most recently served as Worldwide Head, Oncology Drug Research and Development, and at Hoffmann-LaRoche, where he served as Director of Clinical Oncology and Immunology. Dr. Levitt graduated Magna Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Brandeis University. He earned both his medical degree and his post-doctorate degree in Biology from the University of Chicago Pritzker School of Medicine. He completed a residency in Pediatrics at Yale-New Haven Hospital, and a fellowship in Immunology at the University of Alabama in Birmingham. Dr. Levitt was an Assistant Professor in the Department of Pediatrics and Immunology at the University of Chicago Pritzker School of Medicine and was a founding member of the Guthrie Research Institute. | 